Skip to main content

Table 1 Baseline characteristics of 2126 patients who underwent resection for hepatocellular carcinoma stratified by risk of recurrence

From: Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study

Characteristics

Low-risk patients

(n = 1425) (%)

High-risk patients

(n = 701) (%)

P

Gender

0.509

 Male

1244 (87.3)

619 (88.3)

 

 Female

181 (12.7)

82 (11.7)

 

Age (years)

52 (17)

50 (18)

0.001

Tumor number

< 0.001

 Solitary

137 (9.6)

293 (41.8)

 

 Multiple

1288 (90.4)

408 (58.2)

 

Tumor size (cm)

< 0.001

 > 5

246 (17.3)

532 (75.9)

 

 ≤ 5

1179 (82.7)

169 (24.1)

 

 Tumor size (cm)

3.5 (2.2)

8 (4.8)

< 0.001

Tumor location

< 0.001

 Central

389 (27.3)

54 (7.7)

 

 Subcapsular

1036 (72.7)

647 (92.3)

 

Tumor differentiation

0.040

 Poor

194 (13.6)

119 (17)

 

 Moderate and well

1231 (86.4)

582 (83)

 

Tumor MVI

< 0.001

 Yes

87 (6.1)

498 (71)

 

 No

1338 (93.9)

203 (29)

 

BCLC stage

< 0.001

 0/A

1380 (96.8)

482 (68.8)

 

 B

45 (3.2)

219 (31.2)

 

Etiology

0.646

 Non-hepatitis

137 (9.6)

70 (10)

 

 HBV

1267 (88.9)

624 (89)

 

 HCV

21 (1.5)

7 (1)

 

WBC (109/L)

5.8 (2.1)

6.3 (2.5)

< 0.001

RBC (109/L)

4.75 (0.7)

4.8 (0.8)

0.010

Hemoglobin (g/L)

146.5 (17.5)

146 (21.0)

0.360

PLT (109/L)

161 (77)

189.5 (92)

< 0.001

ALT (U/L)

35.7 (25.6)

38.4 (27.5)

0.002

AST (U/L)

31 (16.3)

39.6 (26.6)

< 0.001

ALB (g/L)

43 (4.6)

42.3 (4.8)

< 0.001

TBIL (μmol/L)

13.4 (6.6)

12.5 (6.2)

0.003

PT (s)

11.7 (1.3)

11.7 (1.3)

0.684

ALBI grade

< 0.001

 I

1216 (85.3)

550 (78.5)

 

 II

209 (14.7)

151 (21.5)

 

AFP (ng/mL)

< 0.001

 > 200

468 (32.8)

332 (47.4)

 

 ≤ 200

957 (67.2)

369 (52.6)

 

Cirrhosis

0.092

 Yes

1075 (75.4)

505 (72)

 

 No

350 (24.6)

196 (28)

 

Resection margin (cm)

1 (1.5)

1 (1.0)

< 0.001

Operative blood loss (mL)

< 0.001

 > 400

173 (12.1)

214 (30.5)

 

 ≤ 400

1252 (87.9)

487 (69.5)

 
  1. Values are presented as the median (interquartile range) or n (%)
  2. MVI microvascular invasion, BCLC stage Barcelona clinic liver cancer stage, HBV hepatitis B virus, HCV hepatitis C virus, WBC white blood cell, RBC red blood cell, PLT platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TBIL total bilirubin, PT prothrombin time, ALBI albumin-bilirubin, AFP alpha-fetoprotein